Tracking kidney volume in mice with polycystic kidney disease by magnetic resonance imaging

被引:36
作者
Wallace, D. P. [1 ]
Hou, Y-P [2 ]
Huang, Z. L. [2 ]
Nivens, E. [1 ]
Savinkova, L. [1 ]
Yamaguchi, T. [1 ]
Bilgen, M. [3 ]
机构
[1] Univ Kansas, Med Ctr, Dept Med, Kidney Inst, Kansas City, KS 66160 USA
[2] Univ Kansas, Med Ctr, Hoglund Brain Imaging Ctr, Kansas City, KS 66103 USA
[3] Med Univ S Carolina, Dept Clin Radiol, Charleston, SC 29425 USA
关键词
ADPKD; cystic kidney; kidney volume; renal pathology; progression of renal failure;
D O I
10.1038/sj.ki.5002771
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Polycystic kidney disease is characterized by the progressive enlargement of kidneys due to expanding fluid-filled cysts with the rate of renal volume increase held to be a marker of disease progression. Magnetic resonance imaging (MRI) is used to monitor changes in renal volume in patients with polycystic kidney disease; however, it has not been effectively used in mice to monitor changes in kidney volume during drug treatment studies. We used a powerful 9.4-T horizontal bore magnetic resonance scanner to track changes in kidney volume in pcy/pcy mice, an ortholog of nephronophthisis type 3. Mice were sequentially scanned from 4 to 30 weeks of age and kidney volumes determined from high-resolution images. Kidney volume and maximal cross-sectional surface area correlated positively with kidney weight and the histologic determination of surface area. The increase in kidney volume was exponential up to 20 weeks of age, after which there was a plateau consistent with the replacement of normal parenchyma by fibrotic tissue. Our study demonstrates that MRI accurately determines the rate of kidney volume increase in mice with polycystic kidney disease and hence may be useful in assessing the effectiveness of therapeutic agents to slow disease progression.
引用
收藏
页码:778 / 781
页数:4
相关论文
共 13 条
[1]  
Fei BW, 2005, P ANN INT IEEE EMBS, P467
[2]   METHYLPREDNISOLONE RETARDS THE PROGRESSION OF INHERITED POLYCYSTIC KIDNEY-DISEASE IN RODENTS [J].
GATTONE, VH ;
COWLEY, BD ;
BARASH, BD ;
NAGAO, S ;
TAKAHASHI, H ;
YAMAGUCHI, T ;
GRANTHAM, JJ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1995, 25 (02) :302-313
[3]   Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist [J].
Gattone, VH ;
Wang, XF ;
Harris, PC ;
Torres, VE .
NATURE MEDICINE, 2003, 9 (10) :1323-1326
[4]   Volume progression in polycystic kidney disease [J].
Grantham, JJ ;
Torres, VE ;
Chapman, AB ;
Guay-Woodford, LM ;
Bae, KT ;
King, BF ;
Wetzel, LH ;
Baumgarten, DA ;
Kenney, PJ ;
Harris, PC ;
Klahr, S ;
Bennett, WM ;
Hirschman, GN ;
Meyers, CM ;
Zhang, XL ;
Zhu, F ;
Miller, JP .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (20) :2122-2130
[5]   Early embryonic renal tubules of wild-type and polycystic kidney disease kidneys respond to cAMP stimulation with cystic fibrosis transmembrane conductance regulator/Na+,K+,2Cl- co-transporter-dependent cystic dilation [J].
Magenheimer, Brenda S. ;
John, Patricia. L. St. ;
Isom, Kathryn S. ;
Abrahamson, Dale R. ;
De Lisle, Robert C. ;
Wallace, Darren P. ;
Maser, Robin L. ;
Grantham, Jared J. ;
Calvet, James P. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (12) :3424-3437
[6]   Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosis [J].
Olbrich, H ;
Fliegauf, M ;
Hoefele, J ;
Kispert, A ;
Otto, E ;
Volz, A ;
Wolf, MT ;
Sasmaz, G ;
Trauer, U ;
Reinhardt, R ;
Sudbrak, R ;
Antignac, C ;
Gretz, N ;
Walz, G ;
Schermer, B ;
Benzing, T ;
Hildebrandt, F ;
Omran, H .
NATURE GENETICS, 2003, 34 (04) :455-459
[7]   Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease [J].
Omori, Sayu ;
Hida, Mariko ;
Fujita, Hisayo ;
Takahashi, Hisahide ;
Tanimura, Susumu ;
Kohno, Michiaki ;
Awazu, Midori .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (06) :1604-1614
[8]   Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease [J].
Ruggenenti, P ;
Remuzzi, A ;
Ondei, P ;
Fasolini, G ;
Antiga, L ;
Ene-Iordache, B ;
Remuzzi, G ;
Epstein, FH .
KIDNEY INTERNATIONAL, 2005, 68 (01) :206-216
[9]  
Sullivan LP, 1998, J AM SOC NEPHROL, V9, P903
[10]  
Sun YP, 2002, COMPARATIVE MED, V52, P433